The sodium-glucose cotransporter2 (SGLT2) inhibitors are pharmacologic inhibitors that inhibit the SGLT2 function. In a large-scale clinical study, EMPA-REG OUTCOME, evaluating the safety of 1 of SGLT2 inhibitors, empagliflozin, in the cardiovascular system has been shown to have a significant reduction in risks for primary endpoints including cardiovascular mortality compared with the control groups. 1 The sodium-glucose cotransporter2 inhibitor, canagliflozin, was found to increase low-density lipoprotein-cholesterol (LDL-C) levels during its development. 2 Similar observations have been reported with other inhibitors of SGLT2, suggesting the possibility of a class effect. 3 The mechanism of action is thought to involve the inhibition of glucose reabsorption exerted by SGLT2 inhibitors, leading to an enhancement of compensatory lipid metabolism, thereby affecting body weight reduction and lipid profiles as secondary effects. It is also reported that SGLT2 inhibitor reduces glucose metabolism while enhancing use of lipids, ketones, and branched-chain aminoacids. 4 However, few detailed investigations on such changes in lipid profiles caused by SGLT2 inhibitor have been performed. 2 , 3 In addition, although coronary artery protective effect of high-density lipoprotein-cholesterol (HDL-C), 5 especially large HDL-C has been reported, [6] [7] [8] there are few reports on the effect of SGLT2 inhibitor on HDL-C. 
Introduction
The sodium-glucose cotransporter2 (SGLT2) inhibitors are pharmacologic inhibitors that inhibit the SGLT2 function. In a large-scale clinical study, EMPA-REG OUTCOME, evaluating the safety of 1 of SGLT2 inhibitors, empagliflozin, in the cardiovascular system has been shown to have a significant reduction in risks for primary endpoints including cardiovascular mortality compared with the control groups. 1 The sodium-glucose cotransporter2 inhibitor, canagliflozin, was found to increase low-density lipoprotein-cholesterol (LDL-C) levels during its development. 2 Similar observations have been reported with other inhibitors of SGLT2, suggesting the possibility of a class effect. 3 The mechanism of action is thought to involve the inhibition of glucose reabsorption exerted by SGLT2 inhibitors, leading to an enhancement of compensatory lipid metabolism, thereby affecting body weight reduction and lipid profiles as secondary effects. It is also reported that SGLT2 inhibitor reduces glucose metabolism while enhancing use of lipids, ketones, and branched-chain aminoacids. 4 However, few detailed investigations on such changes in lipid profiles caused by SGLT2 inhibitor have been performed. 2 , 3 In addition, although coronary artery protective effect of high-density lipoprotein-cholesterol (HDL-C), 5 especially large HDL-C has been reported, [6] [7] [8] there are few reports on the effect of SGLT2 inhibitor on HDL-C. 2 
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In this study, we investigated changes in lipids as well as 20 lipoprotein fractions after 3 months of repeated administrations of SGLT2 inhibitor, canagliflozin, in patients with type 2 diabetes.
Aims
In this study, we aimed to examine the details of the effects of SGLT2 inhibitors on lipid profiles. For this, we orally administered 100 mg of canagliflozin per day in patients with type 2 diabetes for 3 months and examined changes in lipid data (triglyceride [ 
Materials and Methods Participants
This study is a multicenter study conducted at 4 clinical facilities and 2 research facilities. The participants were recruited at 4 clinical facilities (Medical Hospital of Tokyo Medical and Dental University, Tokyo, Japan; Asano clinic, Saitama, Japan; Fukuoka University Chikushi Hospital, Fukuoka, Japan; Sugi Hospital, Fukuoka, Japan.). The surveyed population satisfied the following inclusion criteria: (1) patients who were suffering from type 2 diabetes, (2) patients between the age of 20 and 75, and (3) patients who had an HbA1c value (NGSP) of ⩾7.0%. Patients characterized by (1) any acute disorders or infectious diseases; (2) hospitalization; (3) prior to or post-surgery; (4) contraindicated for canagliflozin (Canaglu tablet, 100 mg), that is, with a history of hypersensitivity to the ingredients of the investigational drug, severe ketosis, diabetic coma or precoma, taking diuretic drugs, with renal dysfunction, estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m2 or on dialysis 10 ; or (5) taking fibrates, pioglitazone (Actos), or SGLT2 inhibitors were excluded from the study. The study was approved by the Ethics Committee of all facilities, and it fully complied with the provisions of the Declaration of Helsinki. Informed consent was obtained from all individual participants.
Research design and treatment methods
This study is a multicenter, open-label, single-arm, prospective study. The registration period was February 1 to October 20, 2016. We received informed consent from all participants and then conducted each examination. The study started on July 20, 2017, and followed up until October 20, 2017 . The study design is depicted in Figure 1 . During the pre-visit prior to the start of administration of the investigational drug, the candidates were presented with written consent documents describing the purpose of the study and the potential risks associated with it. After agreeing to consent, patients were interviewed and underwent various tests to determine their eligibility as Figure 1 . The study design: Administration of canagliflozin (CANAGLU Tablets 100 mg) to patients was carried out starting the day after visit 1. Blood tests took place at visit 1 (baseline) and visit 2 (end of the study after 3 months of drug administration).
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well as for exclusion criteria. Once patients met all the criteria, they were registered for the trial.
Administration of canagliflozin (CANAGLU Tablets 100 mg) to patients was carried out starting the day after visit 1, with one 100-mg dose per day taken before or after breakfast via oral administration. The period of administration was set to 3 months to observe increasing LDL levels until they reach a plateau. Observations and blood tests during the period of investigational drug administration took place at visit 1 (baseline) and visit 2 (end of the study after 3 months of drug administration). At each visit, blood sample was taken for blood glucose, lipids, and blood biochemical testing, and samples were provided to the central measurement institution (for measurement and evaluation under uniform conditions).
Fibrate-related drugs and pioglitazone (Actos) were prohibited during the administration of the investigational drug due to its known effects on lipid profiles. The following patient treatments already being taken were allowed during the study: statins for hyperlipidemia treatment, ezetimibe, resin products, probucol, nicotinic acid derivative, polyunsaturated fatty acid, diabetes drugs such as DPP-4 inhibitor, GLP-1 receptor agonists, biguanides, α-glucosidase inhibitors, sulfonylurea drugs, fast acting insulin secretory drugs, and insulin derived drugs. However, they were not allowed to change the usage and dosage as well as be prescribed new drugs.
Measurements for evaluation
The background of registered patients including age (date of birth), sex, height, weight, body mass index (BMI), presence or absence of comorbid hyperlipidemia, and allergies for SGLT2 inhibitors were evaluated during the pre-visit (at the time of registration).
Measurements made for efficacy study at pre-visit, visit 1 (start of administration), and visit 2 (3 months after the start) included HbA1c as a blood glucose evaluation item, 20 detailed lipoprotein fractions (chylomicron-cholesterol [CM-C]), verylow-density lipoprotein-cholesterol (VLDL-C), LDL-C, HDL-C, large HDL-cholesterol (LHDL-C), very large HDL-cholesterol (VLHDL-C), small dense LDL-cholesterol (sd-LDL-C), TC, TG, and non-HDL cholesterol (calculated value) as lipid-related items, body weight, and BMI. The 20 detailed lipoprotein fractions were measured at Skylight Biotech Analysis Center (Akita, Japan) using Lipo SEARCH high sensitivity gel filtration HPLC method.
Measurements made for safety study at pre-visit, visit 1, and visit 2 included subjective and objective symptoms, vital signs (systolic and diastolic blood pressure, heart rate at sitting position), and blood biochemical tests To evaluate the efficacy of the drug, the following 3 points were used as primary measurements: (1) measurements of 20 detailed lipoprotein fractions and their changes in magnitude and ratio from baseline, (2) measurements of blood glucoserelated items and their change in magnitude and ratio from baseline, and (3) measurements of weight and BMI and their change in ratio from baseline.
To evaluate the safety of the drug, the following 3 points were used as sub-primary measurements: (1) measurement of clinical tests (blood biochemical tests) and their changes in magnitude and ratio from baseline, (2) vital measurements and their changes in magnitude and ratio from baseline, and (3) adverse events raised between baseline and visit 2.
Statistical analysis
We evaluated the effects of canagliflozin administration on 20 detailed lipoprotein fractions (cholesterol percentage, particle number), blood glucose (HbA1c) values, body weight, and BMI. The changes in magnitude and ratio from baseline for 20 detailed lipoprotein fractions, HbA1c, body weight, and BMI were determined and statistical significance was evaluated by paired t-test analyses. The changes in magnitude and ratio were defined as below:
Magnitude of change = value after 3 months of starting drug administration -baseline value Ratio of change = magnitude of change / baseline value × 100 (%) Statistical software R (Ver.3.2.4) was used for statistical analysis with a P value < .05 being considered significant.
Results

Participant background
The background of study participants is shown in Table 1 .
Patients consisted of 13 men (59%) and 9 women (41%) with an age of 60.7 ± 11.6, weight 70.0 ± 11.5 kg, and BMI 25.8 ± 3.8. LDL-C values were 121.3 ± 25.3 mg/dL, and the average value showed a value near the upper limit of the normal range. Half of the participants (11 patients) had a history of hyperlipidemia and 6 patients were using statins. HbA1c value was 8.5% ± 1.1%. The usage of diabetes drugs included insulin (1 patient), SU drugs (4 patients), DPP4 inhibitors (16 patients), and other oral drugs (7 patients). There was no difference in sex between the patient background.
Changes in body weight, BMI, and HbA1c
The changes in clinical data are shown in Table 2 . After canagliflozin administration, body weight was significantly reduced from 69.7 to 67.9 kg (P < .001). In parallel with this, BMI decreased from 25.7 to 25.0 (P < .001). Furthermore, HbA1c 
Lipid data and changes in lipoprotein fractions
Lipid data and changes in the main lipoprotein fractions taken before and after canagliflozin administration (visit 1 to visit 2) were shown in Table 3 , respectively. In addition, changes in 20 detailed lipoprotein fractions with particle numbers (nM) of each fraction were shown in Table 4 and Figures 2 and 3 .
Lipid data (Table 3) showed no significant changes in the various cholesterol values measured after 12 weeks of canagliflozin administration including TG, TC, Apo-B, and non-HDL cholesterol. Similarly, 4 main lipoprotein fractions did not show changes in various cholesterol values in CM, VLDL, LDL, and HDL as well as LDL/HDL. The detailed lipoprotein fractions (Table 4 , Figures 2 and 3 ) showed significant increases in cholesterol values in VLHDL (the 20 detailed lipoprotein fractions; total of G14, G15), LHDL (G16), with an increase of 10.9, 11.5%, respectively (P < .05). Furthermore, particle numbers were significantly increased in fraction VLHDL by 10.0% (P < .05). There was no significant change in the other fractions such as S-LDL (the 20 detailed lipoprotein fractions; total of G10, G11, G12, G13) or VS-LDL (same as previous, total of G11, G12, G13).
Safety
Adverse events raised after drug administration in this study were 1 patient for common cold, 3 patients for skin surface and skin abnormalities (acronyx, rash, vulval candidiasis), and 1 patient for stroke. Common cold and acronyx were determined to be adventitious and did not correlate with the investigational drug. Correlations between the investigational drug and rash and vulval candidiasis were not denied. Stroke in this case was determined to be non-serious, and because the patients have underlying arterial sclerosis, the event was determined to have less correlation with the investigational drug.
Safety parameters were shown on Table 2 . As indicated, there was a significant decrease in the vital sign shift in systolic blood pressure from 129.3 to 119.5 mm Hg (P = .008). Furthermore, clinical blood test showed shifts with a significant decrease in values of ALT, ALP, and γGTP and a significant increase in BUN and Cre. However, the changes in values were all within normal ranges. eGFR also showed a significant decrease; however, the difference was small (80.2 to 76.5 mL/min/1.73 m 2 ).
Discussion
There are reports that pharmacologic drugs for hyperlipemia reduce risks for cardiovascular events, and studies have detected changes in lipid profiles before and after administration of fibrate drugs. A study of long-term administration of the fibrate drugs on patients with type 2 diabetes resulted in a significant reduction of cardiovascular event risks compared with the placebo group. In addition, the effects of fibrate drugs on decreases in TG are thought to activate lipoprotein lipase-mediated promotion of very-low-density lipoprotein-1 (VLDL1) catabolic reactions. This leads to LDL-C to grow in size and reduces small dense LDL (sd-LDL) volume. 11 It has been reported that the decreased sd-LDL volume leads to a reduction in cardiovascular event risks regardless of the increase or decrease in enlarged LDL, suggesting sd-LDL is a risk factor for cardiovascular events. 6 Enlarged LDL-C loses the ability to invade vascular subendothelium, which increases its affinity for liver LDL receptors thereby enhancing the metabolism of LDL-C uptake. Therefore, we believe LDL will decrease in the long term even with short-term accumulation of enlarged LDL. Based on the above, we believe the reduction of the volume or changes in the quality of sd-LDL will lead to a reduction in cardiovascular event risks. 12 It was also reported that higher large HDL-C but not medium, small, or total HDL-C is associated with lower cardiovascular risk in a prospective cohort study in 591 patients with stable CAD. Salonen et al 13 reported that large HDL-C levels (HDL2-C) were inversely associated with the risk of acute myocardial infarction and may thus be protective factors with an analysis involving 1799 patients. Similarly, in the Quebec Cardiovascular Study covering 1169 FrenchCanadian men younger than 60 years, large HDL-C (HDL2-C) but not small HDL-C (HDL3-C) was inversely correlated with the incidence of ischemic heart disease. 14 The usage of insulin 2 (8%)
The usage of SU drugs 5 (20%)
The usage of DPP4 inhibitors 16 (64%)
The usage of other oral diabetes drugs 10 (40%)
The usage of statin 7 (28%)
Values expressed as mean ± SD, or number (percent). Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; LDL-C, lowdensity lipoprotein-cholesterol; SBP, systolic blood pressure; SU, sulfonylurea. *P < .05; ***P < .001 between groups.
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Therefore, it has been considered that the cholesterol concentration in specific HDL subpopulations may be more valuable than the TC contained in HDL. Previous reports using empagliflozin 1 have demonstrated reductions in cardiovascular event risks by a type 2 diabetes drug SGLT2 inhibitor, and more recently, canagliflozin was also found to inhibit cardiovascular and renal events (CANVAS trial). 15 As mentioned above, SGLT2 inhibitors such as canagliflozin can affect lipid profiles. At the time of drug development as treatment of type 2 diabetes, increases in LDL-C were observed and it was thought to cause compensatory enhancement of lipid metabolism due to inhibition of blood glucose reabsorption, leading to secondary increases in LDL-C levels. However, the mechanisms as to why the administration of SGLT2 inhibitors alters LDL-C particle size remain unknown. Therefore, it is clinically important to examine particle size or effects on subfractions of LDL or HDL, in patients who were administered SGLT2 inhibitors and their correlation with reductions in cardiovascular event risks.
We should also consider the hypothesis that the changes in lipoproteins with canagliflozin are simply due to improvement Values expressed as mean ± SD, or number (percent). Abbreviations: BMI, body mass index; BW, body weight; DBP, diastolic blood pressure; Hr, heart rate; Post, post-treatment; Pre, pre-treatment; ratio, ratio of change (%); SBP, systolic blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; BUN, blood urea nitrogen; γGTP, γ-glutamyl transpeptidase; CK, creatine kinase. Values with significant differences before and after administration of canagliflozin are marked in bold. *P < .05; **P < .01; ***P < .001 vs pre-treatment. 
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Clinical Medicine Insights: Endocrinology and Diabetes in diabetic control. In type 2 diabetes, there is TG-enrichment of HDL particles; overactive hepatic lipase degrades the TG in those HDL particles, so the HDL particle reduced size and was eliminated through the kidney. 16 Another hypothesis is that canagliflozin improves diabetic control, there is no degradation of HDL particles, and thus there is no reduction in the size of HDL particles, which could explain the increase in very large HDL particles in this study.
There were no significant changes in lipid data (TG, TC, Apo-B), cholesterol in 4 main lipoprotein fractions (CM, VLDL, LDL, HDL), cholesterol in S-LDL, and VS-LDL cholesterol values of 22 patients in the full analysis set (FAS) group before and after canagliflozin administration. Previous reports have consistently found that SGLT2 inhibitors increase both LDL and HDL while slightly reducing TG. 17 In our study, patients have a normal lipid profile (TG 154, HDL 60; Values expressed as mean ± SD, or number (percent). L-VLDL = G3 +G4 + G5, M-VLDL = G6, S-VLDL = G7, L-LDL = G8, M-LDL = G9, S-LDL = G10, VS-LDL = G11 + G12 + G13, VL-HDL = G14 + G15, L-HDL = G16, M-HDL = G17, S-HDL = G18, VS-HDL = G19 + G20. Abbreviations: HDL, high-density lipoprotein; L, large; LDL, low-density lipoprotein; M, medium; Post, post-treatment; Pre, pre-treatment; ratio, ratio of change (%); S, small; VL, very large; VLDL, very-low-density lipoprotein; VS, very small. Values with significant differences before and after administration of canagliflozin are marked in bold. *P < .05; **P < .01 vs pre-treatment. 
